Aurobindo Pharma now weighs mega IPO of Eugia Pharma Specialities to raise around ₹4,500 crore

A second person told Moneycontrol that the plan is to raise around ₹4,500 crore via the proposed IPO. He added that investment banks Axis Capital, Jefferies, Kotak Mahindra Capital and JP Morgan had been shortlisted as advisors along with three law firms. Three other persons also confirmed the above.

"The plan has shifted to the public markets where there is an ongoing wave of new issues. These are early days and the aim is to raise between ₹4,000 crore to ₹5,000 crore via the listing," one of them said, warning that the quantum had not been finalized and may change later depending on market conditions

All the five persons cited above spoke to Moneycontrol on the condition of anonymity. Moneycontrol has sent reminders and is awaiting the response to a detailed email query sent to Aurobindo Pharma.

This article will be updated as soon as we hear from the pharma major. An immediate response could not be elicited from Axis Capital, Kotak Mahindra Capital, Jefferies and JP Morgan.

The domestic pharma and life sciences sector has been active in terms of public issues in the last 8 months. Last month, Bain Capital-backed Emcure Pharma re-filed papers with Sebi for an initial public offer with a reduced size.

Mankind Pharma galvanized the domestic IPO market last year with a blockbuster debut in May. It was followed by healthy debuts in the segment from Concorde Biotech, Blue Jet Healthcare and Innova Captab.

In a disclosure to the bourses on August 25, Aurobindo Pharma said, "The company has already informed the stock exchanges on August 12, 2023, as part of the outcome of its board meeting that it is in the process of exploring all the possibilities of restructuring the business of Eugia Pharma Specialities Limited, a wholly owned subsidiary company focused on sterile/injectables, oncology and hormonal products."

"And as stated earlier, the Committee of Independent Directors will pursue a comprehensive evaluation of various alternatives or options and recommend to the Board for engendering the next horizon of growth as also enhancing value creation to the stakeholders," it added.

The statement was a clarification of a report by The Economic Times, which said Eugia Pharma had been put on the block once again. Incidentally, Aurobindo Pharma's stock price has risen by more than 50% in the last six months.

In May 2021, in a move to improve operational efficiency, the pharma firm approved the transfer of its injectable assets into Eugia Pharma Specialities Limited for “greater focus, attention and specialization” and also to “augment fundraise and strategic tie-ups in future through joint ventures etc” according to exchange disclosures.

According to Aurobindo Pharma's latest annual report, Eugia Pharma, a speciality generic pharmaceutical company, has six manufacturing units located in different locations in India and the US.

The units contribute to the production of a diverse range of differentiated and unique products such as general injectables, oncology, hormonal, penems, penicillin and ophthalmics. According to the Eugia website, the firm is present in 120 plus countries and has 4,000 plus employees and 250 plus globally approved generics.

Eugia's parent parent Aurobindo Pharma was founded in 1986 by P.V. Ramprasad Reddy, K. Nityananda Reddy and a small group of professionals.

According to the firm's website, in addition to being a leading player in semi-synthetic penicillin, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and anti-biotics.